Holen Sie sich die Stockscreener-App
46.61
4.31%
-2.10
Schlusskurs vom Vortag:
$48.71
Offen:
$48.56
24-Stunden-Volumen:
413.64K
Relative Volume:
0.80
Marktkapitalisierung:
$1.39B
Einnahmen:
$232.39M
Nettoeinkommen (Verlust:
$-26.79M
KGV:
-43.14
EPS:
-1.0804
Netto-Cashflow:
$4.41M
1W Leistung:
+1.44%
1M Leistung:
-14.18%
6M Leistung:
-30.33%
1J Leistung:
+35.49%
1-Tages-Spanne:
$46.46
$48.56
1-Wochen-Bereich:
$45.00
$48.83
52-Wochen-Spanne:
$30.27
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
46.61 | 1.39B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
After an $18.03-per-share option exercise, AnaptysBio (ANAB) director sells 5,000 shares. - Stock Titan
Director Hollings C. Renton plans to sell 5,000 AnaptysBio (ANAB) shares valued at about $249K. - Stock Titan
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Zacks Investment Research
Spin-off leaves AnaptysBio (ANAB) a lean royalty firm - Stock Titan
AnaptysBio (ANAB) director adds shares as RSUs vest - Stock Titan
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Canada
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage - investing.com
ANAB Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance UK
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - MarketBeat
U.S. Earnings Preview: After Market Close Sept. 8 - moomoo.com
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB - marketbeat.com
ANAB Q2'26 Earnings: revenue estimate is 8.89M USD - TradingView
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
U.S. Earnings Preview: After Market Close Sept. 1 - Moomoo
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com Nigeria
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com India
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Canada
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com South Africa
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? - Investing.com
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com India
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com UK
Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc. - marketbeat.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio Inc. (ANAB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB - MarketBeat
Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes Position in AnaptysBio, Inc. $ANAB - MarketBeat
ANAB Maintained by TD Cowen -- Price Target Lowered to $70 - GuruFocus
TD Cowen lowers Anaptysbio stock price target to $70 on FDA review - Investing.com UK
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating - Moomoo
TD Cowen lowers Anaptysbio stock price target to $70 on FDA review - Investing.com India
AnaptysBio, Inc. (ANAB) Earnings Preview: The First Full Royalty-Model Quarter Matters More Than the Headline EPS - AlphaStreet
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70 - Moomoo
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - MarketBeat
Greenhaven Road Investment Management, L.P.'s AnaptysBio Inc(ANAB) Holding History - GuruFocus
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup - ChartMill
U.S. Earnings Preview: After Market Close Aug. 18 - Moomoo
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control - Yahoo Finance
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anaptysbio Inc-Aktie (ANAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HOLLINGS C RENTON | Director |
Oct 01 '26 |
Proposed Sale |
49.87 |
5,000 |
249,372 |
0 |
| RENTON HOLLINGS | Director |
Oct 01 '26 |
Sale |
49.87 |
5,000 |
249,372 |
10,995 |
| Orwin John A | Director |
Sep 15 '26 |
Option Exercise |
0.00 |
1,300 |
0 |
17,995 |
| JOE ANTHONY WARE | Director |
Jul 13 '26 |
Proposed Sale |
67.17 |
10,694 |
718,333 |
0 |
| JOE ANTHONY WARE | Director |
Jun 30 '26 |
Proposed Sale |
67.79 |
6,030 |
408,774 |
0 |
| DENNIS MULROY | Officer |
Jun 29 '26 |
Proposed Sale |
63.45 |
9,476 |
601,213 |
0 |
| DENNIS MULROY | Officer |
Jun 26 '26 |
Proposed Sale |
60.82 |
10,000 |
608,183 |
0 |
| DENNIS MULROY | Officer |
Jun 17 '26 |
Proposed Sale |
60.00 |
850 |
51,000 |
0 |
| DENNIS MULROY | Officer |
Jun 16 '26 |
Proposed Sale |
60.00 |
1,265 |
75,900 |
0 |
| DENNIS MULROY | Officer |
Jun 15 '26 |
Proposed Sale |
57.65 |
20,000 |
1,153,014 |
0 |
7.53%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):